FDA Confirms Inclusion of Paediatrics in ACTION3 Study
Filed with ASX · · 3 pages · English
• FDA confirms inclusion of adolescent children (12-17 years old) in ACTION3 global Phase 3 FSGS study is appropriate, increasing the total addressable market for DMX-200 if approved • FSGS is one of the leading causes of kidney failure in children, with 20% of all child nephrotic 1 syndrome cases caused by FSGS • Dimerix is also in discussion with the European Medicines Agency (EMA) regarding a P
Earlier from Dimerix
- DMX-200 FSGS Phase 3 Trial Part 1 Recruitment Achieved
- CLARITY 2.0 COVID-19 Study Outcome
- Chair address and CEO presentation to AGM
- Dimerix Receives A$6.0M R&D Tax Incentive Rebate
- Appendix 4E and 2022 Annual Report
Later from Dimerix
- Successful Completion of DSMB Review of Phase 3 FSGS Trial
- DXB to Receive $2.8m in Prepayment of R&D Tax Incentive
- Half-Year Financial Report & Appendix 4D - 31 December 2022
- Voluntary Suspension
- Entitlement offer and Convertible Note to raise $12 million
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix